Molecular structure of the rabbit α<Subscript>2A</Subscript>-adrenoceptor: a contribution to the α<Subscript>2A</Subscript>-adrenoceptor versus I<Subscript>1</Subscript> imidazoline receptor controversy

In view of the high structural and pharmacological similarities between the alpha(2A)-adrenoceptors of humans and other mammalian species, it has been concluded, in particular, from experiments in rabbits that the (2A)-adrenoceptor is the exclusive site of action of central antihypertensive drugs, although the amino acid sequence of the alpha(2A)-adrenoceptor of just this species was unknown. Therefore, the aim of the present investigation was to determine the complete nucleotide sequence of the coding region of the rabbit alpha(2A)-adrenoceptor gene. Degenerate oligonucleotides corresponding to regions of the alpha(2A)-adrenoceptor conserved between rat and man were used in a polymerase chain reaction with genomic DNA prepared from rabbit. A 1,356-base pair product with an open reading frame of 1,353 base pairs was obtained that encodes a protein of 451 amino acids which is similar to the alpha(2A)-adrenoceptors of other mammals (man, pig, rat, mouse, guinea-pig and cattle) but not to their alpha(2B)- and alpha(2C)-adrenoceptor subtypes suggesting its classification as an alpha(2A)-adrenoceptor. However, the degree of amino acid sequence identity is, at best, only 80% and, thus, about 10% less than between the other mammalian species. Compared with the human sequence there are 81 substantial changes of amino acids. In conclusion, rabbit and human alpha(2A)-adrenoceptors substantially differ in their amino acid sequence which may explain the opposite pharmacodynamic properties of the central antihypertensive drug rilmenidine (alpha(2)-adrenoceptor agonism and antagonism, respectively) reported in the literature. Hence, the present study supports the view that experiments with central antihypertensive drugs in rabbits are not reliably predictive for the site of action of such drugs in man.     

Effect of the blockade of μ<Subscript>1</Subscript>-opioid and 5HT<Subscript>2A</Subscript>-serotonergic/α<Subscript>1</Subscript>-noradrenergic receptors on sweet-substance-induced analgesia

Rationale Sweet-substance-induced analgesia has been widely studied, and the investigation of the neurotransmitters involved in this antinociceptive process is an important way for understanding the involvement of the neural system controlling this kind of antinociception.Objective The aim of this study was to investigate the involvement of opioid and monoaminergic systems in sweet-substance-induced analgesia.Methods The present work was carried out in an animal model with the aim of investigating whether acute (24 h) or chronic (14 days) intake of a sweet substance, such as sucrose (250 g/l), is followed by antinociception. Tail withdrawal latencies in the tail-flick test were measured before and immediately after this treatment. Immediately after the recording of baseline values, independent groups of rats were submitted to sucrose or tap-water intake and, after chronic treatment, they were pretreated with intraperitoneal administration of (1) naltrexone at 0.5, 1, 2 or 3 mg/kg; (2) naloxonazine at 5, 10, 20 or 30 mg/kg; (3) methysergide at 0.5, 1, 2 or 3 mg/kg; (4) ketanserin at 0.5, 1, 2 or 3 mg/kg; or (5) physiological saline.Results Naltrexone and methysergide at two major doses decreased sweet-substance-induced analgesia after chronic intake of a sweet substance. These effects were corroborated by peripheral administration of naloxonazine and ketanserin.Conclusions These data give further evidence for: (a) the involvement of endogenous opioids and a ₁-opioid receptor in the sweet-substance-induced antinociception; (b) the involvement of monoamines and 5HT_2A serotonergic/₁-noradrenergic receptors in the central regulation of the sweet-substance-produced analgesia.     

Neurotensin agonists block the prepulse inhibition deficits produced by a 5-HT<Subscript>2A</Subscript> and an α<Subscript>1</Subscript> agonist

Rationale Neurotensin (NT) agonists have been proposed as potential antipsychotics based exclusively upon their ability to inhibit dopamine-2 (D₂) receptor transmission. Several other pharmacological mechanisms have been implicated in enhancing the antipsychotic profile produced by D₂ inhibition alone. These include inhibition of 5-HT_2A and ₁-adrenoceptors. Recently, we reported that systemic administration of the neurotensin agonist PD149163 blocks deficits in prepulse inhibition (PPI) of the startle reflex produced by the 5-HT_2A receptor agonist DOI. This suggested that NT agonists could inhibit 5-HT_2A modulation of neurotransmission.Objective To determine if other peripherally administered NT agonists shared this effect, we examined the effects of NT69L, another NT agonist, on DOI-induced PPI deficits. In addition, to determine if NT agonists also inhibit ₁-adrenoceptor neurotransmission, we examined the effects of PD149163 and NT69L on PPI deficits induced by the ₁-adrenoceptor agonist, cirazoline.Methods In the NT69L/DOI study, rats received subcutaneous (SC) injections of NT69L (0, 0.1, 1, or 2 mg/kg) followed 30 min later by SC saline or DOI (0.5 mg/kg). In the NT agonist/cirazoline studies, animals received SC injections of either PD149163 (0, 0.01, 0.1, or 1 mg/kg) or NT69L (0, 0.01, 0.1, or 1 mg/kg) followed 30 min later by SC saline or cirazoline (0.7 mg/kg). Animals were tested in startle chambers 20 min later.Results In all three experiments the PPI disruption produced by DOI and cirazoline was blocked by the NT agonists.Conclusions These findings provide strong evidence that NT agonists inhibit 5-HT_2A and ₁-adrenoceptor modulation of neurotransmission, pharmacological effects that, in conjunction with their known inhibition of dopamine transmission, strengthen the antipsychotic potential of NT agonists.     

Selective antagonism of the ataxic effects of zolpidem and triazolam by the GABA<Subscript>A</Subscript>/α<Subscript>1</Subscript>-preferring antagonist β-CCt in squirrel monkeys

Abstract Rationale. Delineation of the receptor mechanisms underlying the behavioral effects of benzodiazepines should allow for the development of drugs with improved clinical utility and reduced side effects. Objectives. The purpose of the present study was to investigate the role of GABA_A/α₁ receptors in the sedative and motor-impairing effects of benzodiazepines. Methods. Squirrel monkeys were tested with the GABA_A/α₁-preferring agonist zolpidem and the nonselective benzodiazepine agonist triazolam alone and in combination with the GABA_A/α₁-preferring antagonist β-CCt and the nonselective benzodiazepine antagonist flumazenil. During 30-min experimental sessions, all occurrences of normal behaviors like locomotion, environment- and self-directed behaviors, as well as side effects such as ataxia, rest and procumbent postures were scored. Results. Zolpidem and triazolam produced dose-dependent reductions in locomotion and environment-directed behavior and increased ataxia and procumbent posture. Triazolam, but not zolpidem, also engendered species-typical rest posture at some doses. Flumazenil antagonized all of the behavioral effects of zolpidem and triazolam, whereas β-CCt antagonized only zolpidem- and triazolam-induced ataxia. Conclusions. GABA_A/α₁ receptor mechanisms appear to play a key role in the ataxic effects of benzodiazepine agonists in squirrel monkeys, similar to recent results with transgenic mice. In contrast to the findings of these recent studies, GABA_A mechanisms other than or in addition to those mediated at the α₁ subunit may play a more important role in the sedative/hypnotic effects of benzodiazepines in squirrel monkeys. Electronic Publication     

Endothelin<Subscript>A</Subscript>–endothelin<Subscript>B</Subscript> receptor cross-talk in rat basilar artery in situ

The rationale for the therapeutic use of dual as opposed to selective endothelin (ET) receptor antagonists stems in part from cross-talk between the ET_A and ET_B receptors. However, whether ET_A–ET_B receptor cross-talk is present in the cerebral vasculature is difficult to discern since findings of cross-talk contrast even among the few reports available. Thus, this study tested whether ET_A–ET_B receptor cross-talk is present in the rat basilar artery. In an in situ cranial window, 0.1 μM sarafotoxin S6c, an ET_B receptor agonist, relaxed basilar artery basal tone by 54%. ET-1 (3 nM) in the absence and presence of 10 μM BQ123, an ET_A receptor agonist, induced 13% contraction and 15% relaxation, respectively. In contrast, the 3-nM ET-1 plateau contraction was relaxed by only ∼50% by 3–10 μM BQ123 and 10 μM BQ610, ET_A receptor antagonists. N^ω-nitro-l-arginine, an NO synthase inhibitor, did not enhance contraction to 3 nM ET-1, suggesting that the partial relaxation of the ET-1 plateau contraction did not involve unmasked endothelial ET_B receptor-mediated relaxation. The ∼50% ET-1 contraction that remained following ET_A receptor antagonist was relaxed by 3–10 μM BQ788, consistent with an ET_B receptor-mediated component of contraction. However, 10 μM BQ788 in the absence of prior ET_A receptor antagonist did not cause relaxation. Subsequent BQ123 addition in the presence of BQ788 completely relaxed the ET-1 contraction. PD145065 (1 μM), an ET_A/B receptor antagonist, completely relaxed 3-nM ET-1 contracted vessels in both the absence and presence of BQ123. These findings suggest that the inability of ET_A receptor antagonist to completely relax the ET-1 plateau contraction in rat basilar artery is due to ET_A–ET_B receptor cross-talk.     

Nandrolone treatment decreases the level of rat kidney α<Subscript>1B</Subscript>-adrenoceptors

Abuse of anabolic androgenic steroids (AAS) is associated with serious side effects, such as hypertension and fluid retention. Renal ₁- and ₂-adrenoceptors are implicated in the regulation of blood pressure and fluid balance. In the present study, the levels of renal _1A-, _1B-, _2A- and _2B-adrenoceptors, and spleen _1B-adrenoceptors, were quantified in tissue membranes from rats treated with the AAS nandrolone decanoate (15 mg/kg) for 14 days. The radioligands used were [³H]-prazosin and [³H]-RX821002. The nandrolone treatment caused a 50% reduction of kidney _1B-adrenoceptors (from 15 fmol/mg protein in control rats to 6.5 fmol/mg protein in treated rats). In contrast, the levels of kidney _1A-, _2A- and _2B-, and spleen _1B-adrenoceptors were unaffected. These results raise the possibility that a decreased level of kidney _1B-adrenoceptors may cause some of the effects observed on blood pressure and fluid balance in heavy abuse of AAS.     

Cross-talk between β<Subscript>1</Subscript>-adrenoceptors and ET<Subscript>A</Subscript> receptors in modulation of the slow component of delayed rectifier K<Superscript>+</Superscript> currents

Delayed rectifier K⁺ currents (I_K) play a critical role in determining cardiac action potential duration (APD). Modulation of I_K affects cardiac excitability critically. There are three components of cardiac delayed rectifier, and the slowly activating component (I_Ks) is influenced strongly by a variety of stimuli. Plasma levels of noradrenaline and endothelin are elevated in heart failure, and arrhythmias are promoted by such humoral abnormalities through modulation of ion channels. It has been reported that protein kinase A (PKA) and protein kinase C (PKC) modulate I_Ks from human minK in a complex manner. In the present study, we coexpressed human minK with the human ₁-adrenoceptor (h₁AR) and the endothelin receptor subtype A (hET_AR) in Xenopus oocytes and investigated the effects of receptor activation on the currents (I_Ks) flowing through the oocytes. ET-1 modulated I_Ks biphasically: a transient increase followed by a decrease. The PKC inhibitor chelerythrine completely inhibited the effects of ET-1. Intracellular EGTA abolished the transient increase by ET-1 and partially inhibited the subsequent decrease in the currents. When I_Ks was increased by 10^–6 M isoproterenol (ISO), ET-1 did not increase but rather decreased the current to an even greater extent than under control conditions. In addition, the effects of ISO on I_Ks were suppressed by ET_AR stimulation. These data indicate that I_Ks can be regulated by cross-talk between the ET_AR and ₁AR systems in addition to direct regulation by each receptor system.     

5-HT<Subscript>1B</Subscript> receptors, α<Subscript>2A/2C</Subscript>- and,to a lesser extent, α<Subscript>1</Subscript>-adrenoceptors mediate the external carotid vasoconstriction to ergotamine in vagosympathectomised dogs

It has previously been suggested that ergotamine produces external carotid vasoconstriction in vagosympathectomised dogs via 5-HT_1B/1D receptors and ₂-adrenoceptors. The present study has reanalysed this suggestion by using more selective antagonists alone and in combination. Fifty-two anaesthetised dogs were prepared for ultrasonic measurements of external carotid blood flow. The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 g/kg; 5-HT_1B), BRL15572 (300 µg/kg; 5-HT_1D), rauwolscine (300 µg/kg; ₂), SB224289 + BRL15572 (300 µg/kg each), SB224289 + rauwolscine (300 µg/kg each), BRL15572 + rauwolscine (300 µg/kg each), rauwolscine (300 µg/kg) + prazosin (100 µg/kg; ₁), SB224289 (300 µg/kg) + prazosin (100 µg/kg), SB224289 (300 µg/kg) + rauwolscine (300 µg/kg) + prazosin (100 µg/kg), SB224289 (300 µg/kg) + prazosin (100 µg/kg) + BRL44408 (1,000 µg/kg; _2A), SB224289 (300 µg/kg) + prazosin (100 µg/kg)+ imiloxan (1,000 µg/kg; _2B), or SB224289 (300 µg/kg) + prazosin (100 µg/kg) + MK912 (300 µg/kg; _2C). Each group received consecutive 1-min intracarotid infusions of ergotamine (0.56, 1, 1.8, 3.1, 5.6, 10 and 18 µg/min), following a cumulative schedule. In saline-pretreated animals, ergotamine induced dose-dependent decreases in external carotid blood flow without affecting arterial blood pressure or heart rate. These control responses were: unaffected by SB224289, BRL15572, rauwolscine or the combinations of SB224289 + BRL15572, BRL15572 + rauwolscine, rauwolscine + prazosin, SB224289 + prazosin, or SB224289 + prazosin + imiloxan; slightly blocked by SB224289 + rauwolscine; and markedly blocked by SB224289 + rauwolscine + prazosin, SB224289 + prazosin + BRL44408 or SB224289 + prazosin + MK912. Thus, the cranio-selective vasoconstriction elicited by ergotamine in dogs is predominantly mediated by 5-HT_1B receptors as well as _2A/2C-adrenoceptor subtypes and, to a lesser extent, by ₁-adrenoceptors.In memoriam: Luis F. Valdivia died on 26 May 2004     

Involvement of the βγ subunits of G proteins in the cAMP response induced by stimulation of the histamine H<Subscript>1</Subscript> receptor

Stimulation of the histamine H₁ receptor has been shown to enhance adenosine 3′, 5′-cyclic monophosphate (cAMP) accumulation in various cell types but, to date, the mechanism by which this occurs is still unclear. In the present study, we examined the possibility that the βγ subunits of G proteins (Gβγ) are involved in this process in cultured Chinese hamster ovary cells transfected with the human histamine H₁ receptor (CHO-H₁). Histamine increased intracellular cAMP levels in a concentration-dependent manner in CHO-H₁ cells, and this histamine action was abolished by pyrilamine (1 μM). Inhibition of histamine H₁ receptor-G_q protein coupling by stable expression of the C-terminal peptide of Gα_q protein significantly attenuated the cAMP accumulation induced by histamine. By comparison, neither BAPTA/AM (50 μM), an intracellular Ca²⁺ chelator, nor GF 109203X (1 μM), an inhibitor of protein kinase C, influenced the cAMP response. Histamine H₁ receptor-mediated cAMP accumulation was significantly inhibited by transient transfection of CHO-H₁ cells with the C-terminal peptide of β-adrenoceptor kinase I (residues 542–685), a scavenger of Gβγ. Stable expression of the C-terminal peptide of the Gα_s protein, but not treatment with pertussis toxin (200 ng/ml for 24 h), attenuated the histamine H₁ receptor-mediated cAMP accumulation. These results suggest that stimulation of histamine H₁ receptors activates adenylyl cyclase through the release of Gβγ subunits from G proteins, thereby elevating intracellular cAMP levels.     

α<Subscript>1</Subscript>-Adrenergic and α<Subscript>2</Subscript>-adrenergic balance in the dorsal pons and gross behavioral activity of mice in a novel environment

Rationale Central α₁- and α₂-adrenoceptors in a number of different brain regions are known to have opposing actions on gross behavioral activity, with the former stimulating and the latter inhibiting activity. Therefore, blockade of α₁-receptors may induce inactivity by leading to unopposed α₂ activity.Objective The aim of this study was to test if central blockade of α₂-receptor function restores behavioral activity in α₁-receptor-blocked mice.Methods Dose-response studies were undertaken on the effects of α₁- and α₂-agonists and antagonists microinjected into the dorsal pons on gross behavioral activity in a novel cage test.Results The behavioral inactivity resulting from blockade of α₁-receptors in the pons with the antagonist, terazosin, was reversed by either a low dose of an α₂-antagonist, atipamezole, or a low dose of an α₂-agonist, dexmedetomidine, but was exacerbated by a high dose of the α₂-agonist.Conclusion The results support the hypothesis that blockade of α₁-receptors in the dorsal pons of mice produces inactivity by causing unopposed activity of α₂-receptors. This condition may be relevant to inactive states seen after stress or during depressive illness.     

Low-affinity interactions of BODIPY-FL-GTPγS and BODIPY-FL-GppNHp with G<Subscript>i</Subscript>- and G<Subscript>s</Subscript>-proteins

BODIPY-FL-guanosine 5'-[-thio]triphosphate (B-GTPS) and BODIPY-FL-guanosine 5'-[,-imido]triphosphate (B-GppNHp) induce fluorescence changes upon binding to purified G_s/G_i-proteins and were suggested to serve as probes for monitoring receptor-mediated G-protein activation. However, B-GTPS and B-GppNHp bound to receptor-G_s/G_i fusion proteins expressed in Sf9 cell membranes with 1,100- to 5,600-fold- and 17- to 55-fold lower affinity than GTPS and GppNHp, respectively. The affinity of B-GTPS/B-GppNHp for G_s/G_i-proteins was considerably lower than the affinity of N-methylanthraniloyl (MANT)-substituted GTP analogs for G_s/G_i-proteins. B-GTPS/B-GppNHp were much less potent than GTPS/GppNHp at regulating adenylyl cyclase (AC) via G_s- and G_i-proteins. B-GTPS/B-GppNHp were similarly efficient as GTPS/GppNHp at activating G_i, but less efficient at activating G_s. In contrast to MANT-GTPS/MANT-GppNHp, B-GTPS/B-GppNHp were inefficient at directly inhibiting AC. In conclusion, the bulky BODIPY group strongly reduces the affinity of GTPS/GppNHp for G-proteins, limiting the use of B-GTPS/B-GppNHp as fluorescence probes.Abbreviations AC Adenylyl cyclase - ₂AR ₂-Adrenoceptor - ₂AR-G_olf Fusion protein consisting of the ₂-adrenoceptor and G_olf - ₂AR-G_sL Fusion protein consisting of the ₂-adrenoceptor and the long splice variant of G_s - ₂AR-G_sS Fusion protein consisting of the ₂-adrenoceptor and the short splice variant of G_s - B-GppNHp BODIPY-FL-guanosine 5'-[,-imido]triphosphate - B-GTPS BODIPY-FL-guanosine 5'-[-thio]triphosphate - FPR-G_i1,2,3 Fusion protein consisting of the formyl peptide receptor and G_i1, G_i2 or G_i3 - G Unspecified G-protein -subunit - G_i Inhibitory G-protein of adenylyl cyclase - G_olf Olfactory G-protein that activates adenylyl cyclase - G_s Stimulatory G-protein of adenylyl cyclase - G_sL Long splice variant of the stimulatory G-protein of adenylyl cyclase, G_s - G_sS Short splice variant of the stimulatory G-protein of adenylyl cyclase, G_s - GppNHp Guanosine 5'-[,-imido]triphosphate - GTPS Guanosine 5'-[-thio]triphosphate - M-GppNHp 2'(3')-O-(N-methylanthraniloyl)-guanosine 5'-[,-imido]triphosphate (MANT-GppNHp) - M-GTPS 2'(3')-O-(N-methylanthraniloyl)-guanosine 5'-[-thio]triphosphate (MANT-GTPS)     

The sigma<Subscript>1</Subscript> (σ<Subscript>1</Subscript>) receptor activation is a key step for the reactivation of cocaine conditioned place preference by drug priming

Rationale Cocaine-seeking behavior can be investigated in rodents using the conditioned place preference (CPP) paradigm, in which the drug-paired environment serves as a conditioned stimulus. Such approach allowed to previously demonstrate the importance of the neuromodulatory sigma₁ (₁) receptor in acquisition of cocaine-induced CPP. CPP can be extinguished and then reactivated, notably using a cocaine challenge (i.e., priming).Objectives and methods In order to examine the role of the ₁ receptor in reinstatement of Cocaine-seeking, Swiss mice acquired CPP with cocaine (30 mg/kg, ip) and then CPP was extinguished.Results A challenge cocaine priming (15 mg/kg) reactivated CPP up to 140% of the post-conditioning response. Pre-administration of the ₁ receptor antagonist BD1047 (330 mg/kg, ip) or repeated treatment with an antisense probe targeting the ₁ receptor prevented CPP reactivation. The ₁ agonist igmesine (1–10 mg/kg, ip) or the steroid dehydroepiandrosterone (DHEA, 10–40 mg/kg, sc) reactivated CPP, in a BD1047-sensitive manner. Moreover, the in vivo [³H](+)-SKF-10,047 binding levels to the ₁ receptor were increased after cocaine conditioning in numerous brain structures and these increases subsisted after extinction. Finally, cross-reactivation of cocaine-induced CPP was observed after phencyclidine (PCP), morphine, nicotine and ethanol administration. However, BD1047 blocked reactivation of CPP induced by PCP, morphine and nicotine but not ethanol.Conclusions Since activation of the ₁ receptor is not sufficient to sustain CPP in naive animals [Neuropsychopharmacology 26 (2002) 444], it is concluded that ₁ receptor activation is a key event for relapse to drug seeking. Activation may occur via sensitization due to enhanced in vivo available of receptors.     

Anticataleptic properties of α<Subscript>2</Subscript> adrenergic antagonists in the crossed leg position and bar tests: differential mediation by 5-HT<Subscript>1A</Subscript> receptor activation

Rationale Recent studies suggest that ₂ adrenoceptor blockade may improve the antipsychotic-like effects of neuroleptics and attenuate dopamine D₂ receptor antagonist-induced catalepsy. However, several ₂ adrenergic antagonists also display serotonin 5-HT_1A receptor agonist activity, which may contribute to anticataleptic actions.Objectives In this study, we examined a series of ₂ adrenergic antagonists to determine the role of activity at serotonin 5-HT_1A receptors in their anticataleptic effects.Methods Catalepsy in rats induced by the antipsychotic haloperidol (2.5 mg/kg, SC) was measured using the cross-legged position (CLP) and bar tests. The compounds examined in this study, in decreasing rank order of ₂ adrenergic versus 5-HT_1A receptor selectivity, were atipamezole, methoxy-idazoxan (RX821002), efaroxan, idazoxan, and yohimbine. Antagonism studies were conducted using the selective 5-HT_1A receptor antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl) cyclohexanecarboxamide dihydrochloride (WAY100635).Results Idazoxan, efaroxan, and yohimbine significantly attenuated the cataleptic effects of haloperidol (2.5 mg/kg, SC) in the CLP test and the actions of their highest doses were significantly blocked by pre-treatment with WAY100635 (0.63 mg/kg, SC). In contrast to the other compounds, methoxy-idazoxan was ineffective in the CLP test. Atipamezole exhibited anticataleptic effects in the bar and CLP tests which were not blocked by WAY100635. Similarly, the anticataleptic effects of methoxy-idazoxan and idazoxan in the bar test were not blocked by WAY100635.Conclusions Serotonin 5-HT_1A receptors play a prominent role in anticataleptic effects of certain ₂ adrenergic antagonists in the CLP test, whereas ₂-adrenergic mechanisms are likely to be primarily responsible for the anticataleptic effects of these ligands in the bar test.     

A new method for evaluating σ<Subscript>2</Subscript> ligand activity in the isolated guinea-pig bladder

We demonstrated the presence of ₂ receptors in the guinea-pig ileum by saturation analysis and extended our investigation to guinea-pig bladder and rat bladder. In functional assays of the isolated tissues in organ baths, ₂ receptor ligands inhibited electrically evoked contractions in both guinea-pig bladder and ileum and a linear correlation was found between ₂ receptor affinity and ₂ receptor activity values of selected compounds. The ₂ activity of these compounds in the presence of desensitised ₁ receptors both in bladder and ileum was also tested. On the basis of our results, we propose the electrically stimulated guinea-pig bladder as a new method for evaluating ₂ activity.     

Aspartate138 is required for the high-affinity ligand binding site but not for the low-affinity binding site of the β<Subscript>1</Subscript>-adrenoceptor

The ₁-adrenoceptor two-site ligand binding hypothesis was investigated by comparing the pharmacological activities of the receptor with an Asp to Glu mutation of amino acid 138 after transient transfection into CHO cells. The high-affinity binding of (–)-[³H]-CGP12177 (pK_D=9.4) and binding inhibition by (–)-isoprenaline (pK_i=6.2), observed with Asp138-₁-adrenoceptors, were absent at Glu138-₁-adrenoceptors. (–)-[³H]-CGP12177 bound with a pK_D=7.6 to Glu138-₁-adrenoceptors and (–)-isoprenaline enhanced binding, probably allosterically. Glu138-₁-adrenoceptors compared with Asp138-₁-adrenoceptors showed a 500,000-fold decrease in cyclic AMP-enhancing potency by (–)-isoprenaline and antagonism by (–)-bupranolol (1 M) was abolished. At Glu138-₁-adrenoceptors, the agonist potency of (–)-CGP12177, compared with (–)-isoprenaline was reduced five-fold, but the antagonism by (–)-bupranolol (pK_B=7.1) was not significantly changed, compared with Asp138-₁-adrenoceptor. Thus, Asp138 of the ₁-adrenoceptor is essential for the binding of (–)-isoprenaline, (–)-bupranolol and (–)-CGP12177 to a high-affinity site, but not for the binding of (–)-CGP12177 and (–)-bupranolol to a low-affinity site.     

Calcium channel function and regulation in β<Subscript>1</Subscript>- and β<Subscript>2</Subscript>-adrenoceptor transgenic mice

Cardiac effects of catecholamines on the L-type calcium channel depend on -adrenoceptor subtype (₁- vs. ₂-adrenoceptor). Chronic overexpression of these receptors leads to hypertrophy and early death at moderate (₁) or excessive (₂) levels of overexpression respectively. In order to examine the role of L-type calcium channels in altered cardiomyocyte calcium homeostasis found with ₁-adrenoceptor overexpression, and to understand the quantitative differences between -adrenoceptor subtypes regarding calcium channel regulation, we examined single channels in myocytes obtained from ₁- and ₂-adrenoceptor transgenic mice. The effects of the agonist isoproterenol were investigated and compared with acute receptor stimulation in the respective non-transgenic littermates.Channels from ₁-adrenoceptor transgenic mice have normal baseline activity, and channel number is not reduced. This contrasts to previous findings with ₂-adrenoceptor transgenic mice, where channel activity is depressed. Isoproterenol is unable to stimulate channel activity in both transgenic models.In conclusion, the L-type calcium channel is not likely to be involved in alterations of calcium handling of ₁-adrenoceptor transgenic myocytes. Furthermore, chronic ₁-adrenoceptor overexpression does not depress channel activity, giving another example of the difference between ₁- and ₂-adrenoceptor signal transduction.K.F. and T.K. equally contributed to this work     

The antipsychotic potential of l-stepholidine—a naturally occurring dopamine receptor D<Subscript>1</Subscript> agonist and D<Subscript>2</Subscript> antagonist

RATIONALE: l-Stepholidine, a dopamine D(2) antagonist with D(1) agonist activity, should in theory control psychosis and treat cognitive symptoms by enhancing cortical dopamine transmission. Though several articles describe its impact on the dopamine system, it has not been systematically evaluated and compared to available antipsychotics. MATERIALS AND METHODS: We examined its in vitro interaction with dopamine D(2) and D(1) receptors and compared its in vivo pharmacokinetic profile to haloperidol (typical) and clozapine (atypical) in animal models predictive of antipsychotic activity. RESULTS: In vitro, l-stepholidine showed significant activity on dopamine receptors, and in vivo, l-stepholidine demonstrated a dose-dependent striatal receptor occupancy (RO) at D(1) and D(2) receptors (D(1) 9-77%, 0.3-30 mg/kg; D(2) 44-94%, 1-30 mg/kg), though it showed a rather rapid decline of D(2) occupancy related to its quick elimination. In tests of antipsychotic efficacy, it was effective in reducing amphetamine- and phencyclidine-induced locomotion as well as conditioned avoidance response, whereas catalepsy and prolactin elevation, the main side effects, appeared only at high D(2)RO (>80%). This preferential therapeutic profile was supported by a preferential immediate early gene (Fos) induction in the nucleus accumbens over dorsolateral striatum. We confirmed its D(1) agonism in vitro, and then using D(2) receptor, knockout mice showed that l-stepholidine shows D(1) agonism in the therapeutic dose range. CONCLUSIONS: Thus, l-stepholidine shows efficacy like an "atypical" antipsychotic in traditional animal models predictive of antipsychotic activity and shows in vitro and in vivo D(1) agonism, and, if its rapid elimination does not limit its actions, it could provide a unique therapeutic approach to schizophrenia.     

Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling of the Dopamine D<Subscript>2</Subscript> Receptor Occupancy of Olanzapine in Rats

Purpose  

A mechanism-based PK-PD model was developed to predict the time course of dopamine D₂ receptor occupancy (D₂RO) in rat striatum following administration of olanzapine, an atypical antipsychotic drug.